PR Newswire Clinical TrialsOriginal article
Dasher Neuroscience achève le recrutement des patients dans le cadre de l'essai clinique mondial de phase II portant sur le YA-101, son principal candidat-médicament développé grâce à l'IA, destiné au traitement de l'atrophie multisystématisée (AMS)
Phase 2YA-101Positive
AI Analysis
Summary
Dasher Neuroscience completed patient recruitment for its global Phase II trial of YA-101, an AI-discovered drug candidate for multisystem atrophy. The trial represents a key milestone in development of the company's lead CNS-targeting therapeutic.
Clinical Trial Data
Phase
2
Outcome Details
Patient recruitment completed in global Phase II clinical trial
Importance:6/10
Sentiment:
0.60
Phase_2_TrialCNS_DrugAI-DiscoveredPatient_RecruitmentRare_Disease
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 29, 2026 7:01 AM